PubMed Health⌕ Search

Biomedical subjects

Erik Rødevand

Publications and source records attributed to Erik Rødevand.

10 recordsLinked to original sources
PubMed2005

[Medical prophylaxis and treatment of steroid induced osteoporosis].

BACKGROUND: Glucocorticoid steroids are widely used as antiinflammatory and immunosuppressive medications and are well known to induce osteoporosis. MATERIAL AND METHODS: Randomised clinical trials and Cochrane reports on the use of calcium, vitamin D, bisphosphonates and hormones were reviewed and the results summarised. Additionally, national and some international recommendations were reviewed in order to propose recommendations for prophylaxis and treatment. The literature was identified by Medline searches. RESULTS AND INTERPRETATION: Calcium and vitamin D prevent bone loss in low-to-medium-dose glucocorticoid steroid therapy. Bisphosphonates maintain or modestly increase lumbar and hip bone mass. The fracture risk was not significantly reduced in the spine and the hip. The clinical randomised trials and Cochrane reports conclude that bisphosphonates as well as calcium and vitamin D taken together are effective and the drugs of choice in prevention and treatment.

Bone Density↗
PubMed2005

[Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].

BACKGROUND: Infliximab and etanercept, both tumour necrosis factor-alpha inhibitors, are proven to be effective in patients with rheumatoid arthritis in randomised controlled trials. MATERIAL AND METHODS: Patients with active rheumatoid arthritis were treated with infliximab (n = 29) or etanercept (n = 24) in clinical hospital practice. They were examined before and during treatment. All patients had tried at least one DMARD before. Details of disease activity were monitored by measuring tender and swollen joints, global and pain patient visual analogue scales, Disease Activity Index Score (DAS 28), the Modified Health Assessment Questionnaire, blood and urine samples, and adverse effects. The patients were monitored regularly for two years or until they stopped treatment. RESULTS: In the infliximab group we observed statistically significantly better values for all the registered variables after 6 weeks. At the other times of registration the variables were varying a lot; however, DAS 28 scores after baseline were all within the limits of moderate effect. In the etanercept group we observed statistically significantly better values for all the variables except for erythrocyte sedimentation rate after 6 weeks. At the other times of registration all the variables had significantly better values. Adverse effects were reported in 9 patients in the infliximab group and in 5 in the etanercept group, but no serious adverse effects were reported. 18 patients in the infliximab group (61%) and 10 in the etanercept group (42%) had stopped treatment within two years, either because of adverse effects or lack of effect. CONCLUSION: In this open study of patients with active rheumatoid arthritis, most experienced a rapid effect of infliximab, but a varying effect later on. In the etanercept group the patients experienced both a rapid and sustained effect among those who tolerated the medication. Compared to what several others have reported, a large number of patients stopped treatment; this may reflect limited experience.

Adult↗
PubMed2005

[Reversible infertility from nonsteroidal anti-inflammatory drugs].

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors may interfere with ovulation and the rupture of the follicle, causing reversible infertility. METHOD: Literature review. RESULTS: Reversible infertility is shown both in animal and human studies of these drugs. As determined by ultrasound, the drugs may delay or inhibit ovulation. These findings are also confirmed by a few randomized controlled studies showing an increase in time from the luteinizing hormone surge to rupture of the follicle and an increased size of the unruptured follicle. Most of the hormone analyses show values in accordance with the ovulation/menstrual cycle. Also, two epidemiological studies have shown an association between NSAID use and spontaneous abortion. These studies have methodological weaknesses and their findings have to be elucidated in future studies. INTERPRETATION: Women with fertility problems should avoid not only the selective cyclooxygenase-2 inhibitors, but also the traditional NSAIDs. However, women with rheumatic disease responding well to therapy should consult their physicians before stopping treatment. Reduced dose of a NSAID and temporary stop of drug treatment early in the menstrual cycle, or alternative drug treatment, may be a solution. NSAIDs should not be used in the last eight weeks of pregnancy.

Abortion, Spontaneous↗
PubMed2005

Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomatosis.

We describe the development of multiple malignancies in a patient with Wegener's granulomatosis treated with glucocorticosteroids, azathioprin and cyclophosphamide over 20 years. His symptoms started with a neurological disease, which is unusual. Less attention was paid to other symptoms that occurred simultaneously and were more typical manifestations of the disease. This resulted in delayed diagnosis. Despite incorrect diagnoses, he received appropriate immunosuppressive therapy. After 2 years of therapy, he developed a spinocellular carcinoma, after 12 years a basal cell carcinoma and after 19 years both a Kaposi sarcoma and a urinary bladder carcinoma. This patient illustrates a difficult therapeutic balance between prolonged treatment and the hazards of therapy. No guidelines are established to manage this clinical dilemma.

Cell Transformation, Neoplastic↗
PubMed2005

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.

OBJECTIVE: To compare the effectiveness of tumor necrosis factor (TNF)-blocking agents (etanercept and infliximab) in patients with rheumatoid arthritis (RA) and patients with ankylosing spondylitis (AS). METHODS: Data from an ongoing longitudinal, observational study in Norway were used to assess changes in health-related quality of life (HRQOL) in patients with RA (n = 291) and AS (n = 62). Patients received anti-TNF therapy, and changes in scores on the Short Form 36 (SF-36), SF-6D, modified Health Assessment Questionnaire, and visual analog scales for patients' assessments of pain, fatigue, and global status from baseline to followup examinations at 3 and 6 months were compared. Data were adjusted for age, sex, and baseline values and are presented as crude estimates as well as standardized response means. RESULTS: Both groups had improvements in all measures at 3 and 6 months. At 3 months, the changes were significantly better in the AS group compared with the RA group for all measures except the SF-36 social functioning scores. At 6 months, all changes were numerically greater in the AS group. Differences were significant for the SF-36 role emotional scores and were borderline significant for the SF-36 physical functioning, role physical, and vitality scores and for the SF-6D scores. CONCLUSION: In this real-life setting, patients with AS experienced improvement in HRQOL that was comparable to, and sometimes greater than, that observed in RA patients. These results support the idea that patients with AS should have the same access to TNF-blocking agents as patients with RA.

Adult↗
PubMed2004

[Side effects off allopurinol].

Allopurinol is generally considered to be a safe and well tolerated drug. We report one patient with a serious effect from allopurinol, a serious exfoliative rash and signs of allopurinol hypersensitivity syndrome. Only after considerable diagnostic delay and patient morbidity, signs and symptoms were associated with the drug. The patient recovered when the medication was withdrawn. Data from the Norwegian reporting system for side effects of drugs for the period 1973-2003 show a wide range of side effects of allopurinol and even some fatalities. The indication for treatment must be carefully considered. Impaired renal function, ampicillin and thiazide diuretics increase the risk of serious hypersensitivity reactions.

Aged↗
PubMed2003

[Training effects on pain in rheumatoid arthritis].

BACKGROUND: This report considers the relationship between the effect of training on pain and joint manifestations in patients with rheumatoid arthritis. METHODS: A review of randomized controlled trials published from 1997 to February 2001. RESULTS: Six randomized controlled trials confirm results from previous research indicating that exercise leads to unchanged or reduced self-reported pain and unchanged or reduced tender joint counts in patients in ACR functional classes I or II with low to moderate disease activity. This effect may possibly be generalized to patients with higher disease activity. The effect is less clearly demonstrated in patients with serious joint destruction and loss of function. INTERPRETATION: The results indicate that exercise leads to unchanged or reduced self-reported pain and joint tenderness for patients with rheumatoid arthritis. Further studies are needed in order to demonstrate to what extent and how different kinds of exercise influence pain and joint tenderness in rheumatoid arthritis patients.

Adult↗
PubMed2003

[Combination therapy in rheumatoid arthritis].

BACKGROUND: During the last decade patients with active rheumatoid arthritis have been offered early and aggressive drug therapy in order to decrease the damaging effect of inflammation on cartilage and bone. Combination of two or more disease-modifying antirheumatic drugs has been used more frequently to achieve better efficacy than with monotherapy without increasing drug side effects. MATERIALS AND METHODS: We have studied available rheumatological literature to find the best documented drug combinations. RESULTS: The combination of methotrexate, sulfasalazine and hydroxychloroquine seems to be a well documented alternative, and so is the combination of methotrexate and cyclosporine. Modern biologic drugs like etanercept, infliximab and anakinra work best in combination with methotrexate. INTERPRETATION: The combination of two or more disease-modifying antirheumatic drugs can be a good alternative to monotherapy in the treatment of patients with active rheumatoid arthritis, either when monotherapy has failed or unacceptable side effects have occurred, or as a first choice in patients who need very early and aggressive therapy. Combination therapy should only be initiated by a rheumatologist, after informed consent. A safe clinical and chemical monitoring must be organized in cooperation with the patient and the primary physician.

Adjuvants, Immunologic↗